| Issue Date | Title | Author(s) |
| 2-Nov-2023 | Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results | Qi, Junyuan; Wei, Xudong; Li, Qiubai; Chang, Chukang; Zhou, Fuling; Huang, Jianying; Zhang, Yu; Xu, Chongyuan; Tang, Xiaowen; Jiang, Qian; Li, Junmin; Qin, Qun; He, Qun; Gao, Sujun; Liu, Liping; Chen, Zi; Yu, Min; Wang, Jing; Men, Lichuang; Wang, Hengbang; Ahmad, Mohammad; Yang, Dajun; Zhai, Yifan; Wang, Jianxiang |
| 15-Nov-2022 | A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China | Jiang, Qian; Li, Zongru; Qin, Ya-Zhen; Zhao, Ting; Liu, Bingcheng; Chen, Zi; Niu, Qian; Men, Lichuang; Wang, Hengbang; Yang, Dajun; Zhai, Yifan; Huang, Xiao-Jun |
| 18-Aug-2022 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 31-Oct-2022 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 20-Feb-2023 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022) | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 2018 | Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study | Jiang, Qian; Huang, Xiao Jun; Chen, Zi; Men, Lichuang; Liu, Wei; Sun, Xuemei; Ji, Jiao; Wang, Hengbang; Hou, Yue; Hu, Po; Zou, Lei; Yan, Hua; Huang, Yingjie; Yang, Dajun; Zhai, Yifan |
| 23-Nov-2021 | Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) | Qian, Jiang; Shi, Dayu; Li, Zongru; Qin, Yazhen; Zhao, Ting; Liu, Bingcheng; Chen, Zi; Niu, Qian; Men, Lichuang; Wang, Hengbang; Yang, Dajun; Zhai, Yifan; Huan, Xiaojun |
